Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
Read More
Tag: GW Pharmaceuticals
GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
Read More
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Jazz will add GW’s plant-derived cannabinoid treatment Epidiolex to its roster
Read More
GW Pharma begins recruitment for US-based Sativex trial
Trial will evaluate Sativex (nabiximols) for multiple sclerosis spasticity
Read More
GW sells priority review voucher for $105m
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
Read More
GW Pharmaceuticals announce quarterly financial results
GW Pharmaceuticals has reported revenue growth of 67.5% for the fourth quarter, driven by demand for Epidiolex.
Read More
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
